Cantor Fitzgerald Predicts GlycoMimetics FY2026 Earnings

GlycoMimetics, Inc. (NASDAQ:GLYC) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of GlycoMimetics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the biotechnology company will post earnings of ($0.03) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for GlycoMimetics’ current full-year earnings is ($0.08) per share.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01.

Separately, Wall Street Zen initiated coverage on shares of GlycoMimetics in a research report on Saturday, May 17th. They set a “sell” rating on the stock.

GlycoMimetics Price Performance

NASDAQ GLYC opened at $0.17 on Wednesday. The firm has a market cap of $10.71 million, a PE ratio of -0.36 and a beta of 1.62. The company has a 50 day moving average price of $0.23 and a 200 day moving average price of $0.25. GlycoMimetics has a 52 week low of $0.14 and a 52 week high of $0.63.

GlycoMimetics’s stock is scheduled to reverse split before the market opens on Monday, June 16th. The 1-100 reverse split was announced on Thursday, June 5th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, June 13th.

Institutional Trading of GlycoMimetics

Several large investors have recently bought and sold shares of the stock. Jefferies Financial Group Inc. grew its position in GlycoMimetics by 38.0% during the 1st quarter. Jefferies Financial Group Inc. now owns 585,000 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 161,223 shares during the last quarter. Wellington Management Group LLP purchased a new stake in GlycoMimetics during the 4th quarter worth approximately $352,000. VR Adviser LLC purchased a new stake in GlycoMimetics during the 4th quarter worth approximately $747,000. Caxton Corp purchased a new stake in shares of GlycoMimetics in the 4th quarter valued at $51,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of GlycoMimetics in the fourth quarter worth $1,268,000. Hedge funds and other institutional investors own 75.19% of the company’s stock.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.